See All Slides - tctmd.com

Slides

Presentation TCT 2025

TCT 244: Biodegradable Coronary Stent

Presenter: Ryan Bruni

October 28, 2025

Presentation TCT 2025

The unique capabilities of PASCAL Precision system

Presenter: Gennaro Giustino

October 28, 2025

Presentation TCT 2025

SYMPHONY PE-IDE Study Results

Presenter: Sripal Bangalore

October 28, 2025

Presentation TCT 2025

TCT 619: Validation of Novel Endpoint for Optimal Drug-eluting stent Implantation in Patients with Acute Coronary Syndrome

Presenter: Hisaki Masuda

October 28, 2025

Presentation TCT 2025

TCT 1159: Deep Learning-BasedDetection and SegmentationofSubclinicalLeafletThrombosison 4DCT After TAVI

Presenter: Victor Alfonso Jimenez Diaz

October 28, 2025

Presentation TCT 2025

TCT 69: Optimal P2Y12 inhibitor strategy after acute coronary syndrome: a network meta-analysis of randomised controlled trials

Presenter: Yousif Ahmad

October 28, 2025

Presentation TCT 2025

Considerations for lifetime management of Severe Aortic Stenosis

Presenter: Aakriti Gupta

October 28, 2025

Presentation TCT 2025

ACS (high risk NSTEMI) with use of Cangrelor

Presenter: Evan Shlofmitz

October 28, 2025

Presentation TCT 2025

TCT 1162: Prognostic Impact of Procedural Urgency Status in TAVR: A Comparative Analysis of In-Hospital and 1-Year Outcomes from a Large Real-World Database

Presenter: Omar Saleh

October 28, 2025

Presentation TCT 2025

TCT 1957: Improved Outcomes for In-Stent Restenosis PCI With Use of Sirolimus Eluting Ultra-thin Stent Platform

Presenter: Jared Romeo

October 28, 2025

Advertisement

Slides

TCT 244: Biodegradable Coronary Stent

The unique capabilities of PASCAL Precision system

SYMPHONY PE-IDE Study Results

TCT 619: Validation of Novel Endpoint for Optimal Drug-eluting stent Implantation in Patients with Acute Coronary Syndrome

TCT 1159: Deep Learning-BasedDetection and SegmentationofSubclinicalLeafletThrombosison 4DCT After TAVI

TCT 69: Optimal P2Y12 inhibitor strategy after acute coronary syndrome: a network meta-analysis of randomised controlled trials

Considerations for lifetime management of Severe Aortic Stenosis

ACS (high risk NSTEMI) with use of Cangrelor

TCT 1162: Prognostic Impact of Procedural Urgency Status in TAVR: A Comparative Analysis of In-Hospital and 1-Year Outcomes from a Large Real-World Database

TCT 1957: Improved Outcomes for In-Stent Restenosis PCI With Use of Sirolimus Eluting Ultra-thin Stent Platform

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content